Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference

DUBLIN, Ireland, Oct. 19, 2016 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Monday, November 7th at 11:00AM MT.

Dr. Heffernan will provide an overview of Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, as well as its therapies in development in the areas of immuno-oncology, inflammation, and allergy.

The presentation will be available on the investor section of Nexvet’s website at following the completion of the event.

About Nexvet (

Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts biomanufacturing in Ireland.

Further information:

Candice Knoll                                                                
Blueprint Life Science Group                                        
+1 415-375-3340 Ext. 4                                                                                                        

Jessica Burns
Berry & Company Public Relations
+1 212-253-8881